Mutations in IDH1 mainly affect R132, which is the binding site for isocitrate, and R132H is the most common alteration, comprising >80% of all IDH1 mutations in gliomas [40,131,132,133]. The gene discussed is IDH1; the disease is central nervous system cancer.